We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 82.50 | 80.00 | 85.00 | 82.50 | 82.50 | 82.50 | 5,234 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -3.77 | 11M |
Date | Subject | Author | Discuss |
---|---|---|---|
10/5/2020 23:14 | It is annoying to see other products being on TV and endorsed by the NHS. Given the chaos in the NHS as witnessed in this pandemic where very highly paid managers can't even provide PPE to frontline clinicians I'm beginning to wonder if the NHS managers can make rational decisions. Feedback have a presence in Pennine Hospitals Trust. It is one of the bigger trusts and has a history of trying new technology which is subsequently taken up by other trusts. I'm not defending the company here because I'm very annoyed that Tom Oakley hasn't answered questions which he should have done. It's about time he stepped up a notch or two, find a few friends in television and get his message across in mainstream media instead of twiddling about on Twitter. | ged5 | |
10/5/2020 22:40 | I think this is the article to which you're referring - it will be interesting to see what effect this has for us tomorrow! | obarmoth | |
10/5/2020 17:47 | The Pando website states that its app can upload and export images, it doesn't qualify the word "images" in any way (eg "clinical grade") so i suppose the question is whether the Bleepa function is superior...it's unlikely that Feedback makes a claim that Bleepa is unique and then cannot back it up, surely! | hipete69 | |
10/5/2020 16:41 | Hi Ged, there have been several messaging claims but I am not aware of any that provide the clinical grade secure imaging that Bleepa affords. Just need to get NHS fully onboard then open up other markets...not much to ask is it, TO could achieve that in his sleep this year (lol). | bobd29 | |
10/5/2020 15:55 | Good to see you posting again, Bob I've just seen some posts on LSE about Panda which I understand is a development of Forward. Hipete69 has stated that Panda is built to deliver clinical grade encrypted messaging. Clinical grade encrypted messaging is different to clinical grade images. From the 20th April RNS Bleepa ® is a secure image-based communication platform which provides access to clinical grade medical images. Bleepa® is the only imaging communication tool that can deliver the required workflow support at the scale required and it's not just Radiologists who need access to imaging now but all frontline personnel. Also it claims to be free, which it is for a basic version not for a bespoke version. | ged5 | |
10/5/2020 12:14 | Agree LR2, the revenues from TexRAD research versions are crucial at present but when/if Bleepa succeeds commercially then TexRAD will be sold. FDBK have given no indication that they intend to progress TexRAD to clinical sales. Great shame imo, great product but it needs a home with large resources to reap commercial benefits. Be interesting to see how many interested buyers and at what price. Next year my guess. | bobd29 | |
09/5/2020 17:50 | I suspect that TexRAD will be sold the moment that Bleepa brings in sufficient revenue. | lr2 | |
09/5/2020 17:41 | Thanks LR2. TexRAD: Develop or sell? I guess with GE Healthcare being left to distribute TexRAD, FDBK will just let it rumble on. It does seem to be used in very many different areas of research. One day it will be found to be necessary in very lucrative clinical use. TexRAD lung? | ged5 | |
09/5/2020 17:26 | Ged, the link doesn't have much info. The full McCoy is held by Springer and they never give much away unless you pay through the nose for it. These scientific / academic media giants really do make money out of next to nothing. The authors of any scientific piece get nothing but are obliged to find a publisher to get their work released to the scientific world. The publisher then charges other interested parties an arm and a leg to read the full document. Even references to TexRAD are often hidden behind the pay wall nowadays. For every one I give a link to there will be 2 or 3 others I don't give a link to because I can't prove to you guys that they are actually talking about TexRAD. Reason I know they exist is a nifty bit of software that tracks down the TexRAD references and flags them even if I can't see the full article in which it appears. I worked on IT systems for a publisher of scientific / academic journals for a few years so I know a bit about the business. | lr2 | |
09/5/2020 17:10 | Sonie, that's very kind of you. You know how to embarrass someone. When he posted on here I posted on the ORPH thread that I'd filtered him for spamming on this thread. So it doesn't much matter what he posts. LR2, I've not yet looked at the TexRAD link but cervical cancer is a very big area and must be awful for those poor women who get it. | ged5 | |
09/5/2020 16:38 | OneDarRodders why you having a go @ Ged? He's a long term holder and posted some very good threads | sonie01 | |
09/5/2020 15:42 | Please someone tel Ged5 I haven't stopped crying since he mentioned he had filtered me. It's devastating !!! LOL Now reality ... Never read anything so sanctimonious in all my years on ADVFN.... "My Thread" ?? its a free BB .. you don't own anything on it at all except your nickname choice now get down off your pathetic soapbox and accept people share related info across all threads. Sheeeshhh | onedayrodders | |
08/5/2020 22:28 | MRI texture features differentiate clinicopathological characteristics of cervical carcinoma Patients with newly diagnosed CC who underwent pre-treatment MRI were retrospectively reviewed. Texture analysis was performed using commercial software (TexRAD). ... Texture features derived from multiple sequences were helpful in differentiating the clinicopathological signatures of CC. The SVM models with selected features from different sequences offered excellent diagnostic discrimination of the tumour characteristics in CC. | lr2 | |
08/5/2020 21:36 | Could be some real excitement at another 'Covid' play ORPH .. a world leader in "Challenge Studies" who have the only purpose built hospital in the world based in London for the same. The WHO have just endorsed the idea of "Challenge Studies" as the way forward for quicker turnaround on results. This is the Who report, huge news for HVIVO (Owned by ORPH) the world leader in challenge studies.... They have more strings to their bow that Covid but this massive opportunity has fallen into their lap. DYOR | onedayrodders | |
08/5/2020 18:13 | Thanks. Don't bother looking. It's from one of the Bleepa videos when he was at the NHS expo in Manchester. I recognised Mike Hayball in the background. You got the only interesting one. | ged5 | |
08/5/2020 17:38 | Hi Ged, I did a search for images of Tom Oakley for the past week and there it was - first in the list. This one also came up but I can't pin it to anything interesting yet. I'll let someone else have a go. Trendy black buttons. | lr2 | |
08/5/2020 09:19 | Just noticed it's a Martha Lane Fox vehicle. | ged5 | |
08/5/2020 09:15 | No it's not been posted LR2. How did you come across that? Thank you! What Digital Leaders do: Help leaders digitally transform their organisations Run programmes and events in 12 UK regions Equip individual leaders with the skills they need to work in digital or start a business Share insightful data, knowledge, insight and stories on the sector to inspire cultural change Connect leaders to the support and services they need Build networks across sectors to encourage unsiloed innovation Why they do it: To support leaders to develop up-to-date, innovative, high quality and efficient public services, including e-services, in areas such as education, health and welfare; Encourage business leaders to use technological tools particularly in small and medium-sized businesses and encourage e-commerce; Share information together and use online services to improve and streamline services provided to citizens; and To promote cross-sector collaboration and to reduce silos Looks like TO wants to get his message across to the people that matter. Let's hope trust managers register. Why the 16th June? Almost 6 weeks off. Ah yes imminently! | ged5 | |
08/5/2020 09:08 | Less of the sarcasm! On almost every thread there is an expert financial advisor telling us to buy because the share price is going to go up 10x or to sell because the company is rubbish. I bet they all know and are making loads of money! Where else would you find so many friendly knowledgeable experts offering free advice. Oh, by the way I'm looking to buy some more next week so you all better sell first thing because this is going to crash! ;-)) | ged5 | |
07/5/2020 21:26 | Ged5 Afraid your wish for people is an impossible outcome, although of course everyone on here makes money ;-) | yump | |
07/5/2020 15:18 | Probably already been mentioned. Can't be bothered to go back and check. If it hasn't, hey, book your place. Only 40 days to go. | lr2 | |
07/5/2020 13:42 | Good luck to them. I hope everybody makes money from share dealing whether short term or long term. I've read elsewhere that a poster here has said that he has a core holding and is trading chunks to bring his average down. | ged5 | |
07/5/2020 13:33 | Is this share being traded by short term traders? Well somebody bought 526 k this morning at 0.95p and has just sold them for 1.047p yielding a profit of 610 stg less expenses. | orange1 | |
07/5/2020 12:50 | Goodness no! I honestly must have been in this for at least 5 years. I've probably seen even more false dawns than you have! | obarmoth | |
07/5/2020 12:34 | lol Forgive me, my memory isn't what it used to be. Are you new to FDBK? Can we thank you for today's rise? | ged5 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions